A recent Cochrane review [191] updated in 2017 including five randomised controlled trials (RCTs) with 205 patients with dystrophinopathies (DMD and BMD) concluded that early treatment with ACE inhibitors or ARBs may be comparably beneficial, and that adding eplerenone might give additional benefit when early cardiomyopathy is detected. The gene discussed is ACE; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.